{"id":"gynoclin-v","safety":{"commonSideEffects":[{"rate":null,"effect":"Vulvovaginal irritation"},{"rate":null,"effect":"Vaginal discharge"},{"rate":null,"effect":"Vulvovaginal candidiasis (secondary yeast infection)"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL380352","moleculeType":"Small molecule","molecularWeight":"584.76"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin is a lincosamide antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, thereby reducing bacterial growth. Gynoclin V delivers clindamycin directly to the vaginal site of infection, allowing for local therapeutic concentrations while minimizing systemic exposure. This formulation is designed to treat bacterial vaginosis and other vaginal infections caused by susceptible anaerobic and aerobic bacteria.","oneSentence":"Gynoclin V is a clindamycin-based vaginal formulation that inhibits bacterial protein synthesis to treat vaginal infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:48.428Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial vaginosis"},{"name":"Vaginal infections caused by susceptible bacteria"}]},"trialDetails":[{"nctId":"NCT01867164","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis","status":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","startDate":"2007-12","conditions":"Vaginitis, Infectious Vaginosis","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gynoclin V","genericName":"Gynoclin V","companyName":"Janssen-Cilag, S.A.","companyId":"janssen-cilag-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gynoclin V is a clindamycin-based vaginal formulation that inhibits bacterial protein synthesis to treat vaginal infections. Used for Bacterial vaginosis, Vaginal infections caused by susceptible bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}